Agenus Inc. — Form 10-Q Summary
Reporting period: Quarter and nine months ended September 30, 2016; filed November 9, 2016. Agenus is an immuno-oncology company developing antibody platforms and candidates, cancer vaccines, and vaccine adjuvants. Its programs are predominantly in discovery, preclinical, or early clinical development.
Financial performance and position
| Metric | Q3 2016 | Q3 2015 | Nine months 2016 | Nine months 2015 |
|---|---|---|---|---|
| Revenue | $4.4 million | $6.8 million | $17.0 million | $17.2 million |
| Research and development expense | $21.6 million | $18.5 million | $69.0 million | $52.5 million |
| General and administrative expense | $8.1 million | $6.4 million | $24.5 million | $19.9 million |
| Operating loss | $36.2 million | $11.1 million | $87.8 million | $62.6 million |
| Net loss | $40.8 million | $13.1 million | $100.9 million | $72.3 million |
| Loss per common share, basic and diluted | $0.47 | $0.16 | $1.16 | $0.95 |
- Revenue was primarily collaboration and license-related, including Incyte cost reimbursements. Nine-month Incyte development-cost reimbursements rose to $11.3 million from $9.6 million; deferred-revenue amortization fell to $3.3 million from $6.7 million.
- At September 30, cash, cash equivalents, and short-term investments totaled $95.4 million, down $76.3 million from December 31, 2015. Current assets were $109.5 million and current liabilities $34.8 million.
- Operating cash use for the first nine months was $63.8 million, versus $27.6 million in 2015. Investing activities provided $6.9 million, while financing activities used $4.6 million. Capital expenditures were $8.2 million.
- Balance-sheet debt was approximately $126.4 million, including current and long-term portions. The filing separately reports $129.6 million of outstanding principal including accrued interest. The $100 million royalty-backed notes accrue interest at 13.5% annually, compounded quarterly; the notes and related obligations are primarily payable from GSK royalties, with Agenus acting as guarantor.
- Accumulated deficit was $879.2 million; stockholders’ deficit was $21.0 million. Common shares outstanding were 87.1 million at September 30.
Changes versus comparable periods
- Q3 revenue declined about 35% year over year; nine-month revenue was nearly flat, down about 1%.
- R&D expense rose about 17% in Q3 and 31% for the nine months, reflecting antibody-program activity, higher headcount, and costs associated with the acquired manufacturing facility. G&A expense increased about 27% in Q3 and 23% for the nine months.
- Nine-month net loss widened by $28.6 million. Interest expense rose to $12.7 million from $2.4 million, principally due to the subordinated notes and royalty monetization financing.
- A $11.0 million Q3 expense from the fair-value increase in contingent purchase-price obligations contributed to the reported quarterly loss; the corresponding nine-month adjustment was an $11.4 million expense. These are valuation adjustments, not necessarily cash payments in the period.
Outlook, commentary, and risks
- Management said available cash and investments were expected to fund operations through the first half of 2017 and expected to seek additional funds before depletion. It may pursue partnerships, asset sales, debt or equity financing, reduce capital spending, or scale back programs. No specific financial guidance was provided.
- Agenus expected to initiate a Phase 1 trial of AutoSynVax within six months. Its anti-GITR and anti-CTLA-4 candidates had begun Phase 1 trials in 2016. GSK filed for U.S. regulatory approval of its shingles vaccine candidate in October 2016; Agenus said the first products containing QS-21 could launch in 2018, subject to development and regulatory outcomes.
- Key risks include ongoing substantial losses and financing needs; clinical, regulatory, manufacturing, and enrollment uncertainty; dependence on Incyte and other collaborators; and uncertainty over GSK vaccine approval, commercialization, and royalties. The royalty-backed notes carry default, put, make-whole, and guarantee provisions that could adversely affect liquidity. Agenus also disclosed significant competition, intellectual-property risks, and foreign-currency exposure.
- Management reported disclosure controls were effective and no material change in internal control over financial reporting occurred during the quarter. No off-balance-sheet arrangements were reported.
Important facts for investors to verify
- Whether financing, partnering, or other actions extend the stated cash runway beyond the first half of 2017, given the higher operating cash burn.
- The full debt economics and contingencies of the royalty-backed notes, including the 13.5% compounded rate, guaranty, and potential payment triggers.
- Progress and cost-sharing obligations under the Incyte collaboration, and clinical milestones for the antibody and AutoSynVax programs.
- GSK’s regulatory and commercial progress for its shingles and malaria vaccines and the resulting royalties available to satisfy the notes.
- Drivers of contingent purchase-price fair-value changes and potential future cash or share obligations from acquisitions.